Benznidazole self-emulsifying delivery system : a novel alternative dosage form for Chagas disease treatment.

Simple item page
dc.contributor.authorMazzeti, Ana Lia
dc.contributor.authorOliveira, Liliam Teixeira
dc.contributor.authorGonçalves, Karolina Ribeiro
dc.contributor.authorSchaun, Géssica C.
dc.contributor.authorMosqueira, Vanessa Carla Furtado
dc.contributor.authorBahia, Maria Terezinha
dc.date.accessioned2020-06-01T14:59:17Z
dc.date.available2020-06-01T14:59:17Z
dc.date.issued2020
dc.description.abstractBenznidazole (BZ) tablets are a unique form of treatment available for treating Chagas disease. Development of a liquid formulation containing BZ easy to administer orally for the treatment of paediatric patients, particularly for newborns is urgently required, with the same efficacy, safety and suitable biopharmaceutical properties as BZ tablets. Self-emulsifying drug delivery systems (SEDDS) may improve bioavailability of drugs such as BZ, which have poor water solubility and low permeability. In this context, the aim of this work was to develop a liquid BZ-SEDDS formulation as an alternative to tablets and to evaluate its cytotoxicity in different host cell lines and its efficacy in experimental Trypanosoma cruzi infection in mice. The optimized SEDDS formulation (25 mg/ml of BZ) induced no cytotoxicity in H9c2, HepG2 and Caco2 cells in vitro at 25 μM level. BZ-SEDDS and free-BZ showed similar in vitro trypanocidal activity in H9c2 cells infected by T. cruzi Y strain, with IC50 values of 2.10 ± 0.41 μM and 1.29 ± 0.01 μM for BZ and BZ-SEDDS, respectively. A follow up of efficacy in an acute model of infected mice resulted in the same percentage of cure (57%) for both free-BZ and BZ-SEDDS- groups according to established parameters. Furthermore, no additional in vivo toxicity was observed in animals treated with BZ-SEDDS. Taken together, in vitro and in vivo data of BZ-SEDDS showed that the incorporation of BZ into SEDDS does not alter its potency, efficacy and safety. Thus, BZ-SEDDS can be a more practical and personalized orally administered liquid dosage form compared to suspension of crushed BZ-tablets to treat newborn and young children by emulsifying SEDDS in different aqueous liquids with advantage of dosing flexibility.pt_BR
dc.identifier.citationMAZZETI, A. L. et al. Benznidazole self-emulsifying delivery system: a novel alternative dosage form for Chagas disease treatment. European Journal of Pharmaceutical Sciences, v. 145, p. 105234, mar. 2020. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0928098720300233?via%3Dihub>. Acesso em: 10 fev. 2020.pt_BR
dc.identifier.doihttps://doi.org/10.1016/j.ejps.2020.105234pt_BR
dc.identifier.issn0928-0987
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/12273
dc.identifier.uri2https://www.sciencedirect.com/science/article/pii/S0928098720300233?via%3Dihubpt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.subjectTrypanosoma cruzipt_BR
dc.subjectCytotoxicitypt_BR
dc.subjectEfficacypt_BR
dc.subjectRelease kineticspt_BR
dc.titleBenznidazole self-emulsifying delivery system : a novel alternative dosage form for Chagas disease treatment.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ARTIGO_BenznidazoleSelfEmulsifying.pdf
Size:
2.6 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
924 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
DEFAR - Artigos publicados em periódicos